Catalio Capital Management LP Buys New Shares in Edwards Lifesciences Corporation $EW

Catalio Capital Management LP bought a new stake in shares of Edwards Lifesciences Corporation (NYSE:EW) during the fourth quarter, Holdings Channel reports. The institutional investor bought 187,048 shares of the medical research company’s stock, valued at approximately $15,946,000. Edwards Lifesciences comprises 3.0% of Catalio Capital Management LP’s holdings, making the stock its 13th biggest holding.

Other institutional investors also recently modified their holdings of the company. Kemnay Advisory Services Inc. acquired a new position in shares of Edwards Lifesciences during the 4th quarter valued at $27,000. JPL Wealth Management LLC acquired a new position in shares of Edwards Lifesciences during the 3rd quarter valued at $25,000. Hilton Head Capital Partners LLC acquired a new position in shares of Edwards Lifesciences during the 4th quarter valued at $28,000. Kohmann Bosshard Financial Services LLC acquired a new position in shares of Edwards Lifesciences during the 4th quarter valued at $28,000. Finally, Dorato Capital Management acquired a new position in shares of Edwards Lifesciences during the 4th quarter valued at $29,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insider Activity

In related news, VP Donald E. Bobo, Jr. sold 23,145 shares of the stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the completion of the transaction, the vice president owned 98,611 shares in the company, valued at approximately $8,521,962.62. This represents a 19.01% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Daniel J. Lippis sold 620 shares of the firm’s stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $81.14, for a total transaction of $50,306.80. Following the sale, the vice president owned 40,411 shares of the company’s stock, valued at $3,278,948.54. This trade represents a 1.51% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 81,038 shares of company stock worth $6,683,255. Company insiders own 0.31% of the company’s stock.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $86.53 on Thursday. The firm has a 50-day moving average of $83.14 and a 200-day moving average of $83.11. The company has a market cap of $49.83 billion, a P/E ratio of 46.03, a P/E/G ratio of 2.22 and a beta of 0.87. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.42 and a quick ratio of 3.63. Edwards Lifesciences Corporation has a one year low of $72.30 and a one year high of $89.60.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.73 by $0.05. The company had revenue of $1.65 billion during the quarter, compared to the consensus estimate of $1.60 billion. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The firm’s revenue for the quarter was up 16.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.64 earnings per share. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Equities research analysts forecast that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Robert W. Baird boosted their target price on shares of Edwards Lifesciences from $85.00 to $87.00 and gave the company a “neutral” rating in a research report on Friday, April 24th. BTIG Research upped their price objective on shares of Edwards Lifesciences from $98.00 to $100.00 and gave the stock a “buy” rating in a report on Friday, April 24th. Wolfe Research upgraded shares of Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 price objective on the stock in a report on Wednesday, April 1st. Evercore restated an “outperform” rating and set a $93.00 price objective on shares of Edwards Lifesciences in a report on Friday, April 24th. Finally, Mizuho set a $95.00 price objective on shares of Edwards Lifesciences and gave the stock an “outperform” rating in a report on Monday, April 13th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat, Edwards Lifesciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $95.96.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.